|Mr. John Lai||CEO, Pres & Director||91.67k||N/A||1962|
|Mr. Randall A. Meyer||COO & Director||15.83k||N/A||1964|
|Dr. David B. Masters Ph.D.||Director of Science & Technology and Director||71.5k||N/A||1958|
|Mr. John F. Dolan||Gen. Counsel, Chief Bus. Devel. Officer, Sec. & Exec. Director||40.25k||N/A||1965|
|Mr. Robert J. Folkes||Chief Financial Officer||N/A||N/A||1963|
|Mr. Gary DeMel||Exec. VP of Bus. Devel.||N/A||N/A||1957|
|Mr. Russell Siakel||Director of Marketing||N/A||N/A||N/A|
|Mr. Mark Middleton||National Director of Sales||N/A||N/A||N/A|
|Mr. Randy Wenthold||Chief Science Officer||N/A||N/A||N/A|
PetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses. The company's pipeline products include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.
PetVivo Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.